Vetter investment will enhance strategic partnership

Start of construction for modern center for visual inspection and logistics

22-Jun-2010 - Germany

A groundbreaking ceremony was held for Vetter’s newest facility, Ravensburg Vetter West. Vetter will build a state-of-the-art high bay warehouse for cold-storage and room-temperature goods. Space will also be dedicated for automatic and manual visual inspection as well as for stability chambers designed to the highest standards. The new facility will allow the company to optimize both its control and logistical processes, which will enable safe and expeditious product delivery to customers. To power the new facility, Vetter will use mostly renewable energy, from photovoltaic cells, biogas and geothermal sources. The first construction phase, scheduled for completion by the end of 2011, is estimated to cost more than 30 million Euros.

“Our investment in a state-of-the-art center for visual inspection and logistics is an investment in our partnership with customers worldwide,” says Vetter Managing Director Thomas Otto. “The facility will broaden the base for our global market supply and underscores our dedication to staying at the forefront of technology.” A highly efficient floor plan and optimized personnel and material flows enable the greatest level of product safety. End-to-end material tracking ensures optimized processes and high traceability. Specially secured storage rooms for visual inspection help prevent product mix-ups and cross-contamination.

The new centre will meet environmental standards as well. Once completed, the new facility will use mainly renewable energy. The storefront will be equipped with photovoltaic cells; for climate control of storage rooms, Vetter will harness geothermal energy, a biogas-fired block heat and power plant and excess energy.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Palmitoylation, a new target for anti-cancer drugs - By developing a tool to visualize the membrane association and activation status of normal and oncogenic proteins, scientists at the UNIGE have established the basis for innovative drug discovery

Palmitoylation, a new target for anti-cancer drugs - By developing a tool to visualize the membrane association and activation status of normal and oncogenic proteins, scientists at the UNIGE have established the basis for innovative drug discovery

Dr. Cecil B. Pickett joins the GVK Biosciences Scientific Advisory Board

Dr. Cecil B. Pickett joins the GVK Biosciences Scientific Advisory Board

Photocure’s Cevira shows positive interim results for treatment of precancerous lesions of the cervix - Six-month interim data presented at international conference addressing prevention of cervical cancer

Horizon Discovery Announces Strategic Partnership with Promega to Develop Next-Generation Predictive Human Disease Models

Triple-threat cancer-fighting polymer capsules for guided drug delivery created

Triple-threat cancer-fighting polymer capsules for guided drug delivery created

New prostate cancer treatment may be riskier

Genzyme and Bayer HealthCare Enter New Strategic Agreement - Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis

Billion-euro takeover: Roche joins the fight against obesity

Billion-euro takeover: Roche joins the fight against obesity

Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity

Immune system reveals new ways to treat brain disease and pain

Genomatix partners with Research Instruments Pte Ltd for Singapore, Malaysia and Thailand markets

The 2013 Nobel Prize in Physiology or Medicine: Machinery regulating vesicle traffic

The 2013 Nobel Prize in Physiology or Medicine: Machinery regulating vesicle traffic